Creative Planning Makes New $56,000 Investment in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Creative Planning bought a new position in Revance Therapeutics, Inc. (NASDAQ:RVNC) in the third quarter, Holdings Channel.com reports. The institutional investor bought 10,858 shares of the biopharmaceutical company’s stock, valued at approximately $56,000.

Other large investors have also added to or reduced their stakes in the company. Certuity LLC bought a new position in Revance Therapeutics in the second quarter worth about $26,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Revance Therapeutics during the second quarter valued at about $33,000. Hsbc Holdings PLC acquired a new position in shares of Revance Therapeutics during the second quarter valued at about $38,000. Nisa Investment Advisors LLC increased its holdings in shares of Revance Therapeutics by 2,167.5% during the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 18,077 shares in the last quarter. Finally, EntryPoint Capital LLC increased its holdings in shares of Revance Therapeutics by 109.4% during the first quarter. EntryPoint Capital LLC now owns 19,906 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 10,400 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Revance Therapeutics Trading Up 2.7 %

Revance Therapeutics stock opened at $4.24 on Thursday. Revance Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $9.74. The stock’s 50 day simple moving average is $5.55 and its two-hundred day simple moving average is $4.43. The firm has a market cap of $444.78 million, a PE ratio of -2.21 and a beta of 0.95.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. On average, equities research analysts forecast that Revance Therapeutics, Inc. will post -1.54 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on RVNC shares. Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Stifel Nicolaus cut their price objective on shares of Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 9th. William Blair reiterated a “market perform” rating on shares of Revance Therapeutics in a report on Monday, August 12th. HC Wainwright reiterated a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a report on Friday, November 8th. Finally, Piper Sandler downgraded shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $9.66.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.